Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04543201 · ClinicalTrials.gov registry record · NA
Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma
A NA study of Glioma, sponsored by University of Rochester.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04543201 is a NA study of Glioma that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 50 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04543201, a NA study of Glioma, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
High grade gliomas (HGGs) are rapidly progressive brain tumors resulting in death for most patients between 6 months and 2 years after diagnosis. It is important for patients with HGG to discuss and document their wishes at the end of life. However, many of these patients experience early changes in cognition which impede their decision-making. For this reason, these patients should have early discussions with their providers. However, implementation of this remains challenging in clinical practice. In this study, we will create an Early STructured Advanced care Referrals by Telehealth (Early START) visit for patients soon after their initial oncology visit. A checklist and pre-visit guide were developed to help guide the visit for both the provider and patient. Providers will receive special training in running these visits. Caregivers and/or family members will be encouraged to participate. Visits will be done using video or telephone and recorded. For patients who do not have access to technology for these visits, it will be provided. After the visit, patients, caregivers and/or family who participated, and providers will fill out surveys to address feasibility of having these extra visits and improve the visits for future. Patients will be followed until death. Caregivers and/or family who participated will be asked about whether end of life was in line with the patient's wishes. We will also use the patient's medical record to assess other aspects of end of life. We will compare end of life outcomes with other similar patients treated at our center.
Conditions Studied
Interventions
- BEHAVIORAL Early START visit using checklist over telephone or zoom
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-10-08 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04543201
The ClinicalTrials.gov registry entry for NCT04543201 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (76% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which Early START visit using checklist over telephone or zoom is the first listed.
NCT04543201 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04543201 about?
NCT04543201 is a clinical study titled "Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma". High grade gliomas (HGGs) are rapidly progressive brain tumors resulting in death for most patients between 6 months and 2 years after diagnosis. It is important for patients with HGG to discuss and document their wishes at the end of life. However, many of these patients experience early changes in...
What is the current status of trial NCT04543201?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2021-10-08. Estimated completion is 2026-07-31.
What conditions does trial NCT04543201 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT04543201?
The interventions under investigation include: Early START visit using checklist over telephone or zoom (BEHAVIORAL).
Who is sponsoring clinical trial NCT04543201?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04543201 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
ASCENT Intervention for Brain Tumor Patients
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.